Douglas E Williams

CIK 1184847 · EVP & President, R&D · last filed 2026-06-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$3.35M
Companies
11
Total Filings
78
Lifetime Open-Market Net
-$3.68M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

BIIB price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
C/O CLIMB BIO, INC.
20 WILLIAM STREET SUITE 145
WELLESLEY HILLS, MA 02481
Related Filers
BIOGEN INC. — 18 joint filings, latest 2015-06-22
ARRAY BIOPHARMA INC — 7 joint filings, latest 2010-11-08
IRONWOOD PHARMACEUTICALS INC — 7 joint filings, latest 2019-04-03
AMGEN INC — 1 joint filings, latest 2002-11-05
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count in each company: direct shares plus every indirect holder (trusts, LLCs, partnerships, family members) on the latest Form 4 that lists them. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CAMP Director — $3.99 — $0 2 2026-06-12
Climb Bio, Inc. (ELYM) Delisted Director — $5.11 — $0 4 2026-06-08
SANA EVP & President, R&D — $1.77 — $0 3 2024-03-08
Codiak BioSciences, Inc. (CDAK) Delisted President & CEO 7,655 $0.06 $436 -$30.7K 8 2023-03-30
OVID Director 5,000 $2.35 $11.7K $32.4K 7 2021-05-18
IRWD Director 87,800 $4.71 $413.5K $0 5 2019-04-03
Regulus Therapeutics Inc. (RGLS) Delisted Director — $8.16 — $0 4 2016-06-03
BIIB EVP Research & Development 11,817 $247.78 $2.93M -$3.73M 16 2015-06-22
Cascadian Therapeutics, Inc. (ONTY) Delisted Director 19,961 — — $0 8 2013-06-14
ZYMOGENETICS INC (ZGEN) Delisted Chief Executive Officer 0 $12.01 $0 $47.0K 12 2010-10-12
ANADYS PHARMACEUTICALS INC (ANDS) Delisted Director 4,500 — — $4.7K 4 2008-05-30

Recent Filings · Page 6 of 8

78 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144, so not all of them end in a sale. Under each notice: the role the filer ticked on it, and whether a sale followed (a Form 4 sale within 30 days, or a sale listed on a later notice).
Filed Symbol Action Net Shares Net $ Link
2012-02-10 BIIB Grant (A) — $0 EDGAR
2012-02-03 BIIB Mixed +3,503 -$200.8K EDGAR
2011-12-07 Cascadian Therapeutics, Inc. (ONTY) Delisted Tax (F) −1,546 -$10.6K EDGAR
2011-06-13 Cascadian Therapeutics, Inc. (ONTY) Delisted Grant (A) +4,538 $0 EDGAR
2011-02-03 BIIB Grant (A) — $0 EDGAR
2010-11-08 — Grant (A) — $0
2010-10-12 ZYMOGENETICS INC (ZGEN) Delisted U −4,600 -$44.9K EDGAR
2010-06-04 Cascadian Therapeutics, Inc. (ONTY) Delisted Grant (A) +8,086 $0 EDGAR
2010-02-02 ZYMOGENETICS INC (ZGEN) Delisted Grant (A) — $0 EDGAR
2009-12-18 ZYMOGENETICS INC (ZGEN) Delisted Mixed — $0 EDGAR
Showing 51–60 of 78
Page 6 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).